Manidipina Sandoz

Manidipine, the active ingredient in Manidipina Sandoz, is a calcium channel blocker presented as a tablet for oral use. It lowers blood pressure in adults with essential hypertension.

GNH USA supplies Manidipina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipine is used to manage hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. - Isolated systolic hypertension: helps control high systolic readings, particularly in older adults.

Manidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation, often on the face. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Nausea: occasional stomach upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or angio‑edema. - Myocardial infarction: rare but reported. - Arrhythmias: abnormal heart rhythms. - Syncope: fainting episodes.

When prescribing or dispensing Manidipina Sandoz, clinicians should consider several safety measures. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Hepatic impairment: use with caution and monitor liver function tests. - Elderly patients: start at lower dose due to increased sensitivity. - Concomitant antihypertensives: adjust doses to prevent additive effects. - Contraindication in severe hypotension or cardiogenic shock. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Manidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Other potent vasodilators: risk of additive hypotension. - Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance blood‑pressure‑lowering effect. - Beta‑blockers: monitor for bradycardia. - NSAIDs: may blunt antihypertensive response.